Emd Serono Inc Company Profile
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What is the competitive landscape for EMD SERONO INC, and when can generic versions of EMD SERONO INC drugs launch?
EMD SERONO INC has six approved drugs.
There are thirteen US patents protecting EMD SERONO INC drugs.
There are one hundred and ninety-two patent family members on EMD SERONO INC drugs in forty-one countries and eighty-three supplementary protection certificates in sixteen countries.
Summary for Emd Serono Inc
| International Patents: | 192 |
| US Patents: | 13 |
| Tradenames: | 6 |
| Ingredients: | 5 |
| NDAs: | 6 |
| Drug Master File Entries: | 2 |
Drugs and US Patents for Emd Serono Inc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Emd Serono Inc | GLUCOPHAGE | metformin hydrochloride | TABLET;ORAL | 020357-005 | Nov 5, 1998 | DISCN | Yes | No | See Plans and Pricing | See Plans and Pricing | |||||
| Emd Serono Inc | TEPMETKO | tepotinib hydrochloride | TABLET;ORAL | 214096-001 | Feb 3, 2021 | RX | Yes | Yes | 8,658,643 | See Plans and Pricing | See Plans and Pricing | ||||
| Emd Serono Inc | MAVENCLAD | cladribine | TABLET;ORAL | 022561-001 | Mar 29, 2019 | RX | Yes | Yes | 8,377,903 | See Plans and Pricing | See Plans and Pricing | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Emd Serono Inc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Emd Serono Inc | GLUCOPHAGE XR | metformin hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 021202-001 | Oct 13, 2000 | 6,660,300 | See Plans and Pricing |
| Emd Serono Inc | CETROTIDE | cetrorelix acetate | POWDER;SUBCUTANEOUS | 021197-002 | Aug 11, 2000 | 6,319,192 | See Plans and Pricing |
| Emd Serono Inc | GEREF | sermorelin acetate | INJECTABLE;INJECTION | 020443-001 | Sep 26, 1997 | 4,517,181 | See Plans and Pricing |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for Emd Serono Inc Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Lithuania | PA2018502 | See Plans and Pricing |
| Austria | 476177 | See Plans and Pricing |
| Japan | 5412709 | See Plans and Pricing |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Emd Serono Inc Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1827461 | C01827461/01 | Switzerland | See Plans and Pricing | PRODUCT NAME: CLADRIBIN; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 66831 19.03.2019 |
| 1412357 | PA2008013,C1412357 | Lithuania | See Plans and Pricing | PRODUCT NAME: SITAGLIPTINUM PHOSPHAS MONOHYDRICUS, METFORMINI HYDROCHLORIDUM; REGISTRATION NO/DATE: EU/1/08/455/001 - EU/1/08/455/014 20080716 |
| 1608344 | C 2018 009 | Romania | See Plans and Pricing | PRODUCT NAME: CLADRIBINA; NATIONAL AUTHORISATION NUMBER: EU/1/17/1212; DATE OF NATIONAL AUTHORISATION: 20170822; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/17/1212; DATE OF FIRST AUTHORISATION IN EEA: 20170822 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
